



Market Data

**Creative Medical
Technology Holdings, Inc.**
Nasdaq: **CELZ**

Fiscal Year	Dec. 31
Price	\$3.26
Market Cap	\$4.4M
Shares Out.	1.34M
Float	1.30M
Avg. Vol. (90-day)	6,898
Cash (mrg)	\$7.5M

Price & share data as of August 28, 2024

Auditor:
Haynie & Company

Legal Counsel:
Fox Rothschild LLP

Transfer Agent:
VStock Transfer LLC

creativemedicaltechnology.com

Company Overview

Creative Medical Technology Holdings is a pioneering commercial-stage biotechnology company specializing in innovative stem cell technologies across the fields of immunotherapy, urology, neurology, endocrinology, and orthopedics. The company's mission is to address significant unmet medical needs through the development and commercialization of regenerative medicine therapies.

Leveraging its proprietary cell-based platforms, Creative Medical has established a robust pipeline of FDA-cleared clinical programs, including breakthrough treatments for chronic lower back pain and Type 1 Diabetes (T1D). The company's lead products, including ImmCelz™ and AlloStem™, utilize cutting-edge human xenofree cell technology, positioning Creative Medical as a leader in the regenerative medicine space.

With a strong financial position, an expanding intellectual property portfolio, and ongoing strategic collaborations, Creative Medical is poised to revolutionize the treatment landscape for a variety of chronic conditions, offering hope to millions of patients worldwide.

Investment Highlights

Innovative regenerative medicine pipeline with breakthrough technologies addressing unmet needs

- Broad portfolio targeting unmet needs in immunotherapy, urology, neurology, endocrinology, and orthopedics
- Lead programs, ImmCelz™ and AlloStem™, leverage xenofree cell technology for personalized treatments addressing Type 1 Diabetes and chronic lower back pain
- Type 1 Diabetes and chronic lower back pain each represent multi-billion-dollar market opportunities
- CELZ-101 received FDA Orphan Drug Designation for brittle Type 1 Diabetes, offering potential market exclusivity

Robust intellectual property portfolio

- Comprehensive patent protections strengthen long-term competitive position

Strategically leveraging artificial intelligence

- AI integration accelerates drug development and enhances personalized treatment plans

Strong financial position

- No long-term debt with cash reserves to support ongoing operations and clinical milestones

Experienced leadership

- Proven management team with a strong track record in advancing biotech innovations

Programs



Value Proposition

Creative Medical Technology is pioneering the next generation of regenerative medicine through its innovative use of stem cell technology and artificial intelligence. The company is at the forefront of developing groundbreaking therapies that address critical unmet medical needs, particularly in the areas of immunotherapy, neurology, and orthopedics.

The company's progress in its Type 1 Diabetes and chronic lower back pain programs underscores its potential to revolutionize how these conditions are treated. With FDA authorizations to proceed with Phase I/II clinical trials in both indications, Creative Medical is advancing therapies that could significantly alter the treatment landscape for these chronic conditions, each multi-billion-dollar market opportunities, offering patients new hope where few effective options exist today.

Creative Medical Technology is also combining the power of AI with human induced pluripotent stem cells (iPSCs) to create personalized, precision treatments. The recent initiation of an AI-driven diagnostic and treatment program for patients exposed to biological and chemical agents showcases the company's ability to rapidly adapt and apply emerging technologies.

Financially, Creative Medical Technology is in a strong position, with sufficient capital to advance its key programs without the immediate need for additional funding. This strategic positioning, combined with a focus on cutting-edge innovation and fiscal responsibility, makes Creative Medical Technology a compelling investment opportunity poised for transformative impact.

Pipeline

Platform	Product / Indication	Patents Filed	Pre-Clinical	Clinical	Comments
AlloStem®	CELZ-201 New Onset Type 1 Diabetes		Clinical		Allogenic Cells IND cleared by FDA
AlloStem®	AlloStemSpine™ Chronic Lower Back Pain		Clinical		Allogenic Cells IND cleared by FDA
AlloStem®	Allova™ Premature Ovarian Failure		Pre-Clinical		Allogenic OvaStem®
ImmCelz®	CELZ-101 Type 1 Diabetes Brittle		Pre-Clinical		ImmCelz with Islet Transplant Orphan Drug Designation
iPSCelz®	Allogenic Cell Program		Pre-Clinical		Multiple Indications Research w/ Greenstone Bioscience
Autologous	StemSpine® Chronic Lower Back Pain		Clinical		Peer Reviewed Publication Journal of Translational Science
Autologous	OvaStem® Premature Ovarian Failure		Clinical		Autologous Cells